Abstract
Stem cell therapy has a place for future application in the treatment of degenerative diseases. Regardless of the origin of the stem cell, when placed within a milieu of inflammatory mediator, they will show varied functions. This review focuses on human mesenchymal stem cells (MSCs) and discusses neuronal replacement using multi- and interdisciplinary approaches. We caution the enthusiasm of scientists since there is always the potential for tumor formation, even for adult stem cells. The review places RE-1 silencing transcription factor (REST) gene as central to the understanding of stem cell behavior in the microenvironment of tissue injury. REST is relevant in the development of dopaminergic and peptidergic neurons from MSCs. Premature downregulation of REST by the pro-inflammatory mediator, IL-1α, can prematurely lead to the expression of neurotransmitters, which in turn, could develop rapid crosstalk with immune cells. In-depth inter- and multi-disciplinary research will lead to rapid and safe translation of MSCs to patients. An understanding of the changes induced in MSCs by cytokines and other mediators will establish future application of MSCs and other stem cells for safe and effective treatments. This study also alludes to the potential of personalized medicine through engineering and mathematics.
Keywords: Mesenchymal stem cells, neurons, cytokines, REST, cancer, aging
Current Stem Cell Research & Therapy
Title: Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair
Volume: 4 Issue: 1
Author(s): Andrew C. Heinrich, Shyam A. Patel, Bobby Y. Reddy, Russell Milton and Pranela Rameshwar
Affiliation:
Keywords: Mesenchymal stem cells, neurons, cytokines, REST, cancer, aging
Abstract: Stem cell therapy has a place for future application in the treatment of degenerative diseases. Regardless of the origin of the stem cell, when placed within a milieu of inflammatory mediator, they will show varied functions. This review focuses on human mesenchymal stem cells (MSCs) and discusses neuronal replacement using multi- and interdisciplinary approaches. We caution the enthusiasm of scientists since there is always the potential for tumor formation, even for adult stem cells. The review places RE-1 silencing transcription factor (REST) gene as central to the understanding of stem cell behavior in the microenvironment of tissue injury. REST is relevant in the development of dopaminergic and peptidergic neurons from MSCs. Premature downregulation of REST by the pro-inflammatory mediator, IL-1α, can prematurely lead to the expression of neurotransmitters, which in turn, could develop rapid crosstalk with immune cells. In-depth inter- and multi-disciplinary research will lead to rapid and safe translation of MSCs to patients. An understanding of the changes induced in MSCs by cytokines and other mediators will establish future application of MSCs and other stem cells for safe and effective treatments. This study also alludes to the potential of personalized medicine through engineering and mathematics.
Export Options
About this article
Cite this article as:
Heinrich C. Andrew, Patel A. Shyam, Reddy Y. Bobby, Milton Russell and Rameshwar Pranela, Multi- and Inter-Disciplinary Science in Personalized Delivery of Stem Cells for Tissue Repair, Current Stem Cell Research & Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488809787169075
DOI https://dx.doi.org/10.2174/157488809787169075 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry Progress in Self-assembling Peptide-based Nanomaterials for Biomedical Applications
Current Topics in Medicinal Chemistry Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry <I>In-silico</I> Molecular Interaction of Short Synthetic Lipopeptide/Importin-alpha and <I>In-vitro</I> Evaluation of Transgene Expression Mediated by Liposome- Based Gene Carrier
Current Gene Therapy Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition
Anti-Cancer Agents in Medicinal Chemistry In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Calcium-suppressed Technique in Dual-layer Detector Computed Tomography to Evaluate Knee Articular Cartilage
Current Medical Imaging Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Preclinical Evaluation of New Taxoids
Current Pharmaceutical Design MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma
Current Radiopharmaceuticals Assessment of MicroRNA-15a and MicroRNA-16-1 Salivary Level in Oral Squamous Cell Carcinoma Patients
MicroRNA